Evra Patch Combination* Patch POM, R x9

EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch

Therapeutic indications:
• Female contraception
• EVRA is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.
• The decision to prescribe EVRA should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with EVRA compares with other CHCs

Features

Nature and contents of container:
• Primary packaging material - A sachet is composed of four layers: a low-density polyethylene film (innermost layer), an aluminium foil, a low-density polyethylene film, and an outer layer of bleached paper.
• Secondary packaging material - Sachets are packaged in a cardboard carton.
•Every carton has 3, 9 or 18 EVRA transdermal patches in individual foil-lined sachets.
•Sachets are wrapped per three in a transparent perforated plastic film and packed in a cardboard carton.

Special precautions for storage:
• Store in the original package in order to protect from light and moisture.
• Do not refrigerate or freeze.

Shelf life:
• 2 years